- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Oncology Tool Provides Weekly Performance and Market Share Analytics
IntrinsiQ Specialty Solutions (Frisco, TX), a part of AmerisourceBergen, has announced the launch of MarketTREND, an interactive, visual tool that provides oncology manufacturers with product performance and market share analytics on a weekly basis.
The tool pulls treatment data from practices’ in-office dispensing and inventory management solutions and compiles it in an online portal, which can be segmented based on the tumor type and/or class of drug the manufacturer is seeking to analyze. Through this system, manufacturers can evaluate the drug’s uptake, market share (e.g., total treatment share vs. new patient starts), how it is performing relative to other drugs in the same category, and how it is affecting the use of those comparable drugs.
Susan Weidner, Senior Vice President of Analytics at IntrinsiQ Specialty Solutions, commented: “Manufacturers are eager to obtain this type of information, especially for products that are highly-targeted, entering crowded markets, or heavily used in the community oncology space. MarketTREND’s reports give manufacturers a significant competitive advantage by providing the valuable insights needed to make more informed decisions about their products more quickly.”
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
